<?xml version="1.0" encoding="UTF-8"?>
<p id="p0625">Favipiravir, an anti-influenza drug approved in Japan, interferes with viral replication and it is a potential inhibitor of RNA-dependent RNA-polymerase. A randomized study, conducted in a Chinese medical centre, compared umifenovir (200 mg*3/day) and favipiravir (1600 mg*2/first day followed by 600 mg*2/day) showing that, unlike umifenovir, favipiravir did not significantly improve the clinically recovery rate at Day 7 
 <xref rid="b0855" ref-type="bibr">[171]</xref>.
</p>
